C Kesch1, J P Radtke2,3, F Distler2, S Boxler4, T Klein2, C Hüttenbrink2, K Hees5, W Roth6, M Roethke3, H P Schlemmer3, M Hohenfellner2, B A Hadaschik2. 1. Urologische Universitätsklinik Heidelberg, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. Claudia.Kesch@med.uni-heidelberg.de. 2. Urologische Universitätsklinik Heidelberg, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. 3. Abteilung für Radiologie, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland. 4. Universitätsklinik für Urologie, Universität Bern, Bern, Schweiz. 5. Institut für Medizinische Biometrie und Informatik, Heidelberg, Deutschland. 6. Pathologisches Institut der Universität Heidelberg, Universität Heidelberg, Heidelberg, Deutschland.
Abstract
BACKGROUND: Multiparametric MRI (mpMRI) plays an increasingly important role in prostate cancer (PCa) diagnostics and is recommended in men with previously negative TRUS biopsy. The optimal biopsy method after mpMRI is under discussion. OBJECTIVE: Prospective, PIRADS- and START-conform analysis of the relevance of mpMRI and MRI-TRUS fusion biopsy in patients with prior negative TRUS biopsy and comparison of the detection rates of fusion-targeted biopsies (tB) and systematic transperineal saturation biopsies (sB). MATERIALS AND METHODS: Between 10/2012 and 09/2015, 287 patients with prior negative TRUS biopsy underwent mpMRI and software-assisted, rigid MRI-TRUS fusion biopsy. In addition to and strictly separated from sB (median cores n = 24), tB (median cores per patient n = 4, per lesion n = 3) were performed in case of suspicious MRI lesions (PIRADS ≥ 2). Both biopsy methods were compared by using McNemar's test. RESULTS: Of the 287 patients, 148 (52 %) had positive biopsies. Of these, 108/287 (38 %) had significant PCa (Gleason Score [GS] = 3 + 3 and PSA ≥ 10 ng/ml or GS ≥ 3 + 4) and again 43/287 (15 %) had a GS ≥ 4 + 3 PCa. sB failed to diagnose 8/148 PCa (5.4 %) and 6/108 significant PCa (5.5 %), whereas tB failed to diagnose 48 (32.4 %) PCa (p < 0.0001) and 22 (20.4 %) significant PCa (p = 0.0046). Of the PCa missed by tB, 11 had a GS ≥ 3 + 4 and 5 of these a GS = 4 + 3. On a per patient basis, MRI failed to detect 5 significant PCa, whereby 17 of the significant PCa were missed by fusion-targeted cores alone. CONCLUSIONS: In men with unsuspicious MRI (PIRADS < 3), there is a 11 % risk of significant PCa. In case of suspicious MRI lesions, the combination of both biopsy approaches offers maximum tumor detection.
BACKGROUND: Multiparametric MRI (mpMRI) plays an increasingly important role in prostate cancer (PCa) diagnostics and is recommended in men with previously negative TRUS biopsy. The optimal biopsy method after mpMRI is under discussion. OBJECTIVE: Prospective, PIRADS- and START-conform analysis of the relevance of mpMRI and MRI-TRUS fusion biopsy in patients with prior negative TRUS biopsy and comparison of the detection rates of fusion-targeted biopsies (tB) and systematic transperineal saturation biopsies (sB). MATERIALS AND METHODS: Between 10/2012 and 09/2015, 287 patients with prior negative TRUS biopsy underwent mpMRI and software-assisted, rigid MRI-TRUS fusion biopsy. In addition to and strictly separated from sB (median cores n = 24), tB (median cores per patient n = 4, per lesion n = 3) were performed in case of suspicious MRI lesions (PIRADS ≥ 2). Both biopsy methods were compared by using McNemar's test. RESULTS: Of the 287 patients, 148 (52 %) had positive biopsies. Of these, 108/287 (38 %) had significant PCa (Gleason Score [GS] = 3 + 3 and PSA ≥ 10 ng/ml or GS ≥ 3 + 4) and again 43/287 (15 %) had a GS ≥ 4 + 3 PCa. sB failed to diagnose 8/148 PCa (5.4 %) and 6/108 significant PCa (5.5 %), whereas tB failed to diagnose 48 (32.4 %) PCa (p < 0.0001) and 22 (20.4 %) significant PCa (p = 0.0046). Of the PCa missed by tB, 11 had a GS ≥ 3 + 4 and 5 of these a GS = 4 + 3. On a per patient basis, MRI failed to detect 5 significant PCa, whereby 17 of the significant PCa were missed by fusion-targeted cores alone. CONCLUSIONS: In men with unsuspicious MRI (PIRADS < 3), there is a 11 % risk of significant PCa. In case of suspicious MRI lesions, the combination of both biopsy approaches offers maximum tumor detection.
Authors: Timur H Kuru; Karan Wadhwa; Richard Tsung Meng Chang; Lina Maria Carmona Echeverria; Matthias Roethke; Alexander Polson; Giles Rottenberg; Brendan Koo; Edward M Lawrence; Jonas Seidenader; Vincent Gnanapragasam; Richard Axell; Wilfried Roth; Anne Warren; Andrew Doble; Gordon Muir; Rick Popert; Heinz-Peter Schlemmer; Boris A Hadaschik; Christof Kastner Journal: BJU Int Date: 2013-06-17 Impact factor: 5.588
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Erik Rud; Dagmar Klotz; Kristin Rennesund; Eduard Baco; Viktor Berge; Diep Lien; Aud Svindland; Eskild Lundeby; Rolf E Berg; Lars M Eri; Heidi B Eggesbø Journal: BJU Int Date: 2014-12 Impact factor: 5.588
Authors: Jeremy P Grummet; Mahesha Weerakoon; Sean Huang; Nathan Lawrentschuk; Mark Frydenberg; Daniel A Moon; Mary O'Reilly; Declan Murphy Journal: BJU Int Date: 2014-02-19 Impact factor: 5.588
Authors: Christian Arsov; Robert Rabenalt; Dirk Blondin; Michael Quentin; Andreas Hiester; Erhard Godehardt; Helmut E Gabbert; Nikolaus Becker; Gerald Antoch; Peter Albers; Lars Schimmöller Journal: Eur Urol Date: 2015-06-23 Impact factor: 20.096
Authors: G L Shaw; B C Thomas; S N Dawson; G Srivastava; S L Vowler; V J Gnanapragasam; N C Shah; A Y Warren; D E Neal Journal: Br J Cancer Date: 2014-04-10 Impact factor: 7.640
Authors: Malte Kroenig; Kathrin Schaal; Matthias Benndorf; Martin Soschynski; Philipp Lenz; Tobias Krauss; Vanessa Drendel; Gian Kayser; Philipp Kurz; Martin Werner; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Mathias Langer; Cordula A Jilg Journal: Biomed Res Int Date: 2016-11-21 Impact factor: 3.411